AstraZeneca: picks AI-generated drug target
(CercleFinance.com) - Britain's BenevolentAI said on Wednesday that AstraZeneca had selected a first AI-generated drug target from their collaboration deal.
The move means that the target for chronic kidney disease (CKD) - that was predicted by Benevolent's platform - is now entering AstraZeneca's development portfolio after the drugmaker validated it through experimental testing.
In 2019, BenevolentAI and AstraZeneca entered a strategic collaboration aiming to discover new drugs for CKD and idiopathic pulmonary fibrosis.
The partnership combines AstraZeneca's scientific expertise with BenevolentAI's target identification platform and biomedical knowledge graph to identify new drug targets.
Copyright (c) 2021 CercleFinance.com. All rights reserved.